Placental products lift 12-week closure of diabetic foot ulcers

Design

Systematic review and random-effects meta-analysis of randomised and quasi-randomised trials, PROSPERO registered

Population

944 adults with active diabetic foot ulcers across 9 standard-care-controlled comparisons

Primary outcome

Complete wound closure at 12 weeks

Effect

59.0% vs 35.8%; RR 1.70 (95% CI 1.31 to 2.20), I² 51.9%, prediction interval 0.93 to 3.11

A meta-analysis pooled nine standard-care-controlled comparisons of placental, amniotic or umbilical cord products in adults with active diabetic foot ulcers. In 944 participants, complete closure at 12 weeks occurred in 298 of 505 treated (59.0%) and 157 of 439 controls (35.8%), a risk ratio of 1.70 (95% CI 1.31 to 2.20). The review was registered, used a random-effects model and rated certainty as moderate.

The result held when single studies were left out, when odds ratios were used, and when the one high-risk-of-bias trial was excluded. Heterogeneity was moderate (I² 51.9%), and the prediction interval ran from 0.93 to 3.11. That means the average benefit is real in this dataset, but a new product or clinic could see little or no gain.

In practice this supports these products as an adjunct once offloading, infection control, perfusion assessment and debridement are already in place. It does not replace any of them. The pooled trials mixed different products, so the finding is about the class, not any single brand.

• Confirm offloading, infection control, debridement and perfusion before considering an adjunct
• Placental products were tested as add-ons to standard care, never as substitutes
• Set a review point: a wound that has not shrunk meaningfully by 4 weeks needs reassessment, not just a new dressing
• Ask whether the specific product has its own randomised data; the pooled effect does not transfer automatically
• Cost and availability matter in India; check local access before promising an option

Why it matters

Wound-product use has often run ahead of endpoint-specific randomised evidence, and this gives a measured estimate of what the class adds.

Don't overread it

The pooled effect averages different products, and the prediction interval crossing 1 means individual products may not match it.

The statistics, in plain English

A risk ratio of 1.70 means closure was about 70% more likely with the product than without. The confidence interval (1.31 to 2.20) excludes 1, so the average effect is unlikely to be chance. The prediction interval (0.93 to 3.11) describes where a future trial might land and it crosses 1, so a particular product or setting may show no benefit. I² of about 52% signals that the trials differed noticeably from one another.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.